Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
Status:
Completed
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
Gemcitabine is a novel analog of the nucleoside deoxycytidine that acts via inhibition of DNA
synthesis.Docetaxel is a semisynthetic taxane and promotes microtubule assembly and inhibits
microtubule depolymerization.
In this study, patients received gemcitabine 900 mg/m2 on days 1 and 8 plus docetaxel 100
mg/m2 on day 8 with G-CSF support every 3 week.